Cet anticorps Souris Monoclonal détecte spécifiquement CD33 dans FACS, WB, IP, IHC (fro), ICC, Func et MS. Il présente une réactivité avec des échantillons de Humain et Non-Human Primate. Il a été cité dans 8+ publications.
The mouse monoclonal antibody WM53 reacts with an extracellular epitope of CD33, a 67 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells, it is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.
Purification
Purified by protein-A affinity chromatography.
Pureté
> 95 % (by SDS-PAGE)
niveau d'endotoxine
Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
Garnache-Ottou, Chaperot, Biichle, Ferrand, Remy-Martin, Deconinck, de Tailly, Bulabois, Poulet, Kuhlein, Jacob, Salaun, Arock, Drenou, Schillinger, Seilles, Tiberghien, Bensa, Plumas, Saas: "Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells." dans: Blood, Vol. 105, Issue 3, pp. 1256-64, (2005) (PubMed).
Leone, Rutella, Bonanno, Abbate, Rebuzzi, Giovannini, Lombardi, Galiuto, Liuzzo, Andreotti, Lanza, Contemi, Leone, Crea: "Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function." dans: European heart journal, Vol. 26, Issue 12, pp. 1196-204, (2005) (PubMed).
Schenk, Bouchon, Birrer, Colonna, Mueller: "Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 174, Issue 1, pp. 517-24, (2004) (PubMed).
Vitale, Romagnani, Puccetti, Olive, Costello, Chiossone, Pitto, Bacigalupo, Moretta, Mingari: "Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, Issue 10, pp. 5764-9, (2001) (PubMed).
Shin, Choi, Kim, Chung, Chung, Park, Jung, Kim, Park, Kim, Park, Min, Kim, Park: "Expression of leukemia-associated antigen, JL1, in bone marrow and thymus." dans: The American journal of pathology, Vol. 158, Issue 4, pp. 1473-80, (2001) (PubMed).
Bradstock, Kirk, Grimsley, Kabral, Hughes: "Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations." dans: British journal of haematology, Vol. 72, Issue 4, pp. 512-8, (1989) (PubMed).
Favaloro, Bradstock, Kabral, Grimsley, Zowtyj, Zola et al.: "Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging ..." dans: British journal of haematology, Vol. 69, Issue 2, pp. 163-71, (1988) (PubMed).
Favaloro, Bradstock, Kabral, Grimsley, Berndt: "Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, 'gp67' (CD-33)." dans: Disease markers, Vol. 5, Issue 4, pp. 215-25, (1988) (PubMed).
Antigène
CD33
Autre désignation
CD33
Sujet
CD33 Molecule,CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies, these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia.,SIGLEC3, p67